Immuneering Corporation
IMRX
Rank in Stocks
#15941
Immuneering Corporation is a biopharmaceutical company dedicated to developing... Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Share Price
$3.65
Last synced: 2026-11-09
Market Cap
$236.39M
Change (1 day)
-0.82%
Change (1 year)
-45.85%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Immuneering Corporation (IMRX)
Category
Healthcare
EPS for Immuneering Corporation (IMRX)
EPS as of September 2026 TTM: $-1.03
According to Immuneering Corporation's latest financial reports, its current EPS (TTM) is $-1.03. At the end of 2025 the company had an EPS of $-1.27, an increase over its 2024 EPS of $-2.04.
EPS history for Immuneering Corporation from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.03 | -18.90% |
| 2025 | $-1.27 | -37.75% |
| 2024 | $-2.04 | 8.51% |
| 2023 | $-1.88 | 0.53% |
| 2022 | $-1.87 | 47.24% |
| 2021 | $-1.27 | 0.79% |
| 2020 | $-1.26 | 110.00% |
| 2019 | $-0.60 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,620.39% |
US
|
|
| $-7.07 | 586.41% |
US
|
|
| $-5.29 | 413.59% |
AU
|
|
| $12.88 | -1,350.50% |
BE
|
|
| $21.56 | -2,193.20% |
NL
|
Questions about Immuneering Corporation's earnings per share (EPS)
What is Immuneering Corporation's earnings per share (EPS)?
Immuneering Corporation's earnings per share (EPS) over the last twelve months is $-1.03, as of Sep 2026.
What was Immuneering Corporation's earnings per share (EPS) in 2025?
In 2025, Immuneering Corporation's earnings per share (EPS) was $-1.27, compared with $-2.04 in 2024.
How has Immuneering Corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Immuneering Corporation's earnings per share (EPS) was highest in 2020 ($-1.26) and lowest in 2024 ($-2.04).
How does Immuneering Corporation's earnings per share (EPS) compare with similar companies?
Immuneering Corporation's earnings per share (EPS) ($-1.03) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.